Last reviewed · How we verify
Linaprazan glurate - High dose
Linaprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the gastric H+/K+-ATPase pump to reduce gastric acid secretion.
Linaprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the gastric H+/K+-ATPase pump to reduce gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Acid-related disorders.
At a glance
| Generic name | Linaprazan glurate - High dose |
|---|---|
| Sponsor | Cinclus Pharma Holding AB |
| Drug class | Potassium-competitive acid blocker (P-CAB) |
| Target | H+/K+-ATPase (gastric proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Unlike proton pump inhibitors (PPIs) that irreversibly bind the H+/K+-ATPase, linaprazan competitively blocks potassium binding to the pump, allowing for faster onset and offset of acid suppression. This mechanism may provide more consistent 24-hour pH control and potentially faster healing of acid-related lesions. The glurate salt formulation is designed to improve bioavailability and tolerability.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Acid-related disorders
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |